BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an ...
Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based contrast agent was well ...
Bayer revealed first results of the pediatric study from the pivotal clinical development program QUANTI for its low-dose MRI contrast agent QUANTI Pediatric evaluated the pharmacokinetics and safety ...
“Interstitial fluid flow measuring has always been a challenge for understanding of the tumour microenvironment, which drives the development of an applicable characterization method for quantitative ...
ISMI offers a radiologist-led Full-Body MRI in Montreal to identify life-saving findings, detect health risks, and support timely decisions. Whole-body MRI can reveal life-altering findings but may ...
MRI contrast agents, which are typically gadolinium-based, are used to enhance visualization of abnormal structures or lesions and to aid differentiation between healthy and pathological tissue. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback